Last Patient Dosed in Part 2 of Verrica’s Phase 2 Study of VP-315 in BCC
The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. VP-315 is a chemotherapeutic administered intratumorally. It works by inducing lysis of intracellular organelles of tumor cells such as mitochondria, thereby unleashing a broad spectrum of […]